Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00085839
Status:
COMPLETED
Last Update Posted:
2012-08-09
First Post:
2004-06-15
Brief Title:
Erlotinib vs Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer NSCLC and Eastern Cooperative Oncology Group ECOGPerformance Status PS 2
Sponsor:
OSI Pharmaceuticals
Organization:
Astellas Pharma Inc
Study Overview
Official Title:
A Randomized Phase II Study of Single Agent Erlotinib Tarceva TM OSI-774 Versus Standard Chemotherapy in Patients With Previously Untreated Advanced NSCLC and a Poor Performance Status
Status:
COMPLETED
Status Verified Date:
2012-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this noncomparative study is to obtain preliminary estimates of the efficacy of erlotinib and standard chemotherapy in patients with advanced previously untreated nonsmall cell lung cancer NSCLC and an Eastern Cooperative Oncology Group ECOG performance status PS of 2 The study will also evaluate the safety of single-agent erlotinib in this patient population
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None